Targeting GD2 after allogeneic SCT: effector cell composition defines the optimal use of ch14.18 and the bispecific antibody construct NG-CU (GD2-CD3).
Cancer Immunol Immunother
; 72(11): 3813-3824, 2023 Nov.
Article
in En
| MEDLINE
| ID: mdl-37742286
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Antibodies, Bispecific
/
Neuroblastoma
/
Antineoplastic Agents
Limits:
Humans
Language:
En
Journal:
Cancer Immunol Immunother
Journal subject:
ALERGIA E IMUNOLOGIA
/
NEOPLASIAS
/
TERAPEUTICA
Year:
2023
Document type:
Article
Affiliation country:
Alemania
Country of publication:
Alemania